Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.
The user has been using finasteride and minoxidil, then switched to dutasteride and minoxidil for six months without significant results, noticing thinning after increasing creatine dosage. They plan to consult a dermatologist to explore potential causes beyond androgenetic alopecia.
PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
People discussing their experiences with hair loss treatments found that switching from finasteride (Fin) to dutasteride (Dut) often resulted in improved hair thickness and health, despite some experiencing side effects or shedding phases. Some users switched due to diminishing results with Fin, while others were curious about the potential for better outcomes with Dut.
Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.
TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.
The user has been using finasteride and minoxidil for hair loss but is considering switching to dutasteride due to insufficient results, particularly for hairline improvement. Other users shared their experiences with dutasteride, noting potential benefits and side effects, and suggested a gradual transition from finasteride to dutasteride.
The conversation discusses skepticism about new hair loss treatments, with many users expressing doubt about the effectiveness and availability of future solutions. Current treatments like minoxidil, finasteride, and hair transplants are mentioned as reliable options.
RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.
The conversation revolves around how balding has made the original poster and others hyper-aware of other men's hairlines, often judging the severity of their hair loss and whether they've had treatments like hair transplants, minoxidil, or finasteride. Some participants express a need for therapy due to their obsession, while others joke about their newfound "expertise" in assessing hair loss.
The user discussed switching from RU58841 with Minoxidil to Finasteride due to cost, noting better physical feelings and hair growth with RU58841. They are considering returning to RU58841 and checking DHT levels after a month.
The conversation discusses hair loss treatments, specifically progesterone therapy with hydrocortisone butyrate, and the use of dutasteride and finasteride. Opinions vary on the effectiveness and side effects of these treatments, with some users advocating for acceptance of balding if treatments are not suitable.
Switching from finasteride to dutasteride and oral minoxidil worsened hair thinning at the hairline and temples. The user is considering returning to finasteride, as dutasteride may not be effective for them.
User Kylo313 used dutasteride for 20 years and had two daughters, questioning if dutasteride affects the likelihood of having male vs female children. Replies mostly request hairline photos and discuss anecdotal experiences, with some suggesting correlation doesn't imply causation and that gender determination isn't affected by dutasteride.
Finasteride increased testosterone levels from 900 ng/dl to 1200 ng/dl without side effects, improving hair condition. Access to finasteride and minoxidil varies by country, with some places requiring prescriptions and others offering easy access.
A 31-year-old male considering returning to finasteride at a lower dose or using topical finasteride to assess his Norwood scale for a potential future hair transplant. He previously stopped finasteride due to side effects and has been shaving his head.
The user experienced hair loss while using finasteride for over 2 years, but saw slight improvement after switching to dutasteride. They also started using a scalp moisturizer for seborrheic dermatitis, which may have contributed to the hair regrowth.
Hair transplant success largely depends on individual biology, with many patients needing multiple procedures to achieve satisfactory density. Even top surgeons can't guarantee results, and many people use additional treatments like Minoxidil and Finasteride.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Users question effectiveness of HMI-115 and consider waiting longer for results.
The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.
The conversation is about the release of Phase 3 trial results for pyrilutamide in China for treating hair loss. The user is inquiring if the actual results have been posted, noting that a recent release did not contain them.
A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
The conversation discusses the potential for high doses of dutasteride to completely inhibit scalp DHT and speculates whether this could cure baldness when combined with a topical antiandrogen. Specific dosages mentioned are 0.5 mg reducing scalp DHT by 55% and 2.5 mg by about 79%.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
The user has been using minoxidil and finasteride for 3.5 months and has seen a 20% improvement in hair density. They are advised to continue treatment and consider switching agents or adjusting dosages if needed.
PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.
The conversation discusses a user's experience with switching from finasteride to dutasteride for hair loss and noticing a decrease in hair density. They question if finasteride could be more effective than dutasteride for some people, while others suggest that shedding is normal and it takes time to see results from dutasteride.
The user has been experiencing diffuse hair thinning despite using finasteride, minoxidil, dermarolling, clobetasol cream, and PRP sessions. They seek advice on additional treatments and are advised to check vitamin D, iron, and thyroid levels.
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.